Modified PEG-Lipids Enhance the Nasal Mucosal Immune Capacity of Lipid Nanoparticle mRNA Vaccines
The 1.5 mol% of chitosan-modified LNPs (mRNA-LNP-1.5CS) can serve as a safe and effective carrier for intranasal mRNA vaccines, offering a promising strategy for combating the Omicron variant.
Authors
- Haonan Xing (ORCID: https://orcid.org/0000-0001-6251-3643)
- Zengming Wang (ORCID: https://orcid.org/0000-0001-6695-4403)
- Xiwei Wang (ORCID: https://orcid.org/0000-0001-6953-9790)
- Jing Yi
- Aiping Zheng (ORCID: https://orcid.org/0000-0001-8870-0914)
- Hui Zhang (ORCID: https://orcid.org/0000-0003-2535-5046)
- Nan Liu (ORCID: https://orcid.org/0000-0001-8982-1582)
- Ting Liu (ORCID: https://orcid.org/0000-0003-1816-5551)
- Meng Li (ORCID: https://orcid.org/0000-0002-5646-4926)
- Yicheng Lu (ORCID: https://orcid.org/0009-0007-9717-5112)
Institutions
- Yanbian University (CN)
- Capital Medical University (CN)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-11-07
- DOI
- https://doi.org/10.3390/pharmaceutics16111423
- Citations
- 4
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Key Research and Development Program of China